Abstract:Background The aim of this study was to characterize the variable phenotypes and outcomes associated with the methylmalonic aciduria and homocystinuria type C protein gene (MMACHC) c.482G > A mutation in 195 Chinese cases with CblC disease.Methods We carried out a national, retrospective multicenter study of 195 Chinese patients with CblC disease attributable to the MMACHC c.482G > A variant either in a homozygous or compound heterozygous state. The control group consisted of 200 patients diagnosed with CblC disease who did not possess the c.482G > A mutation. Clinical features, including disease onset, symptoms, biochemical metabolites, gene mutation, and follow-up outcomes were reviewed and analyzed in detail. The median follow-up period spanned 3 years and 8 months, with a range of 1 year and 2 months to 12 years and 10 months.Result s Among 195 patients carrying the c.482G > A variant, 125 (64.1%) cases were diagnosed by newborn screening (NBS), 60 (30.8%) cases were detected due to disease onset, and 10 (5.1%) cases were identified from sibling diagnoses. One hundred and seventeen (93.6%) individuals who were diagnosed by NBS, and nine patients who came from sibling diagnoses remained asymptomatic in this study. From 69 symptomatic patients of the c.482G > A group, more patients presented with later onset, and the top six common clinical symptoms at disease onset were developmental delay (59.4%), lower limb weakness and poor exercise tolerance (50.7%), cognitive decline (37.7%), gait instability and abnormal posture (36.2%), seizures (26.1%), and psychiatric and behavioral disturbances (24.6%). In the 159 symptomatic patients lacking c.482G > A variants, the most frequently observed clinical manifestations at disease onset included developmental delay (81.8%), lethargy and feeding difficulty (62.9%), lower limb weakness and poor exercise tolerance (54.7%), prolonged neonatal jaundice (51.6%), vomiting (47.2%), and seizures (32.7%). Before treatment, the levels of blood propionylcarnitine, propionylcarnitine/acetylcarnitine ratio, and homocysteine in the c.482G > A group were significantly lower (P < 0.05) than those in the non-c.482G > A group, while the concentration of urinary methylmalonic acid was slightly lower (P > 0.05). The degree of decline in the above metabolites after treatment in different groups significantly differed in both plasma total homocysteine values and urinary methylmalonic acid levels (P < 0.05). In patients carrying the c.482G > A variant compared with the non-c.428G > A group, there were markedly lower rates of mortality (0.5% vs. 2.0%) and developmental delay (20.5% vs. 65.5%). When compared with individuals diagnosed due to disease onset, those identified through NBS in either group exhibited a reduced proportion of disease onset (6.7% vs. 100% in the c.482G > A group, 54.4% vs. 100% in the non-c.482G > A group), lower mortality (0.0% vs. 1.7% in the c.482G > A group, 0.0% vs. 3.6% in the non-c.482G > A group), and had a higher percentage of patients exhibiting normal psychomotor and language development (99.3% vs. 33.3% in the c.482G > A group, 58.9% vs. 10.9% in the non-c.482G > A group).Conclusions The c.482G > A variant in MMACHC is associated with late-onset and milder phenotypes of CblC disease. Patients with this mutation tend to have a relatively better response to hydroxocobalamin, better metabolic control, and more favorable neurological outcomes. NBS and other appropriate pre-symptomatic treatments seem to be helpful in early diagnosis, resulting in favorable clinical outcomes.

Clinical data analysis of cblC methylmalonic acidemia combined with homocysteinemia

Clinical, Biochemical, and Molecular Analysis of Combined Methylmalonic Acidemia and Hyperhomocysteinemia (cblc Type) in China

[Genetic Analysis of Newborns with Abnormal Metabolism of 3-Hydroxyisovalerylcarnitine].

Analysis of MUT gene mutations in a patient with isolated methylmalonic acidemia]

The First Case of Cobalamin F Disorder in China: Report and Literature Review

Late-onset Cblc Defect: Clinical, Biochemical and Molecular Analysis

Clinical and Molecular Genetic Analysis with Methylmalonic Acidemia Combined with Homocystinuria

Clinical Characteristics and Genotype Analysis of Five Infants with Cblx Type of Methylmalonic Acidemia

Clinical analysis and outcome of patients with c. 482G >A variant of MMACHC gene in cblC type methylmalonic acidemia

[Analysis of Gene Mutations in Chinese Patients with Methylmalonic Acidemia and Homocysteinemia].

Variable Phenotypes and Outcomes Associated with the MMACHC C.482g > A Mutation: Follow-Up in a Large CblC Disease Cohort

[Factors Affecting Phenotypes in the Patients with MMACHC Gene C.609g>a Homozygous Variant Cblc Type Methylmalonic Acidemia Combined with Homocysteinuria].

Combined Methylmalonic Aciduria and Homocystinuria Cblc Type of a Taiwanese Infant with C.609g>a and C.567dupt Mutations in the MMACHC Gene

Analysis of clinical data in 143 patients with methylmalonic acidemia

Variable Phenotypes and Outcomes Associated with the MMACHC C.609g>a Homologous Mutation: Long Term Follow-Up in a Large Cohort of Cases

Late-onset methylmalonic acidemia and homocysteinemia (cblC disease): systematic review

Clinical Features and Outcomes of Patients with Cblc Type Methylmalonic Acidemia Carrying Gene C.609g>a Mutation.

[A Chinese Boy with Methylmalonic Aciduria Cblb Type and a Novel Mutation in the MMAB Gene].

Case report: An asymptomatic mother with an inborn error of cobalamin metabolism (cblC) detected through high homocysteine levels during prenatal diagnosis

Clinical and Gene Mutation Analysis in Patients with Methylmalonic Acidemia and Homocystelnemia

Case Report: A Case of Adult Methylmalonic Acidemia With Bilateral Cerebellar Lesions Caused by a New Mutation in MMACHC Gene